板块方面，AI医疗概念股表现强势。除阿里健康外，微创机器人-B、医渡科技等个股也录得上涨。大 型科技股走势出现分化，阿里巴巴-W、哔哩哔哩-W、快手-W收盘上涨，而美团-W、京东集团-W等则 出现下跌。 其他市场动态方面，全球智能产品设计与制造服务提供商龙旗科技于1月14日启动招股，计划全球发售 5225.91万股H股，预计于1月22日在联交所开始买卖。 港股市场于1月14日收盘上涨。恒生指数收报26999.81点，上涨151.34点，涨幅为0.56%；恒生科技指数 收报5908.26点，上涨38.47点，涨幅为0.66%。 在主要指数成分股中，阿里健康成为当日涨幅最高的恒指成分股。该股当日大幅上涨。消息面上，阿里 健康于1月13日宣布，与北京梅尔森医药技术开发有限公司达成战略合作，推动全球首款获批用于治 疗"增殖期浅表性婴儿血管瘤"的外用创新药"贝美净"在其平台全网独家首发。此外，公司重要股东阿里 巴巴集团将于1月15日举办其人工智能应用"千问"的发布会。另一方面，阿里健康作为持股5%以上的股 东，于1月13日公告计划减持A股上市公司漱玉平民不超过2%的股份，减持原因为自身资金需求。 另一家科技公司携程集团 ...

Group 1 - The Hang Seng Index rose by 0.92%, gaining 245 points to close at 27,094, while the Hang Seng Tech Index increased by 1.54% [1] - Zhipu (02513) surged over 16% after launching the first domestic chip training multimodal SOTA model in collaboration with Huawei [1] - Alibaba (09988) saw a rise of over 5% as it significantly increased its capital expenditure budget for Alibaba Cloud, with institutions expecting earnings resilience to exceed expectations [1] - Alibaba Health (00241) jumped over 15% after the exclusive launch of Beimei Jing, which received the first overseas drug price certification [1] - Yidu Tech (02158) rose over 9% after winning first place in a smart healthcare innovation competition, showcasing its strong AI medical innovation capabilities [1] Group 2 - Tongdao Liepin (06100) soared over 10% due to deepening AI strategy and stable financials leading to market revaluation [2] Group 3 - Baiaosaitu-B (02315) increased over 6% after completing the localization of its AI-driven antibody drug development platform [3] - Maifushi (02556) rose over 8%, with its stock price nearly doubling in the past three weeks after launching the GEO smart assistant [3] - MicroPort Robotics-B (02252) gained over 8%, as the surgical robot industry is expected to enter a commercialization and policy acceleration phase [3] - Hua Hong Semiconductor (01347) increased over 5%, with Goldman Sachs noting high capacity utilization supporting product mix optimization and price increases [3] - Restaurant stocks led the gains, with institutions expecting most leading restaurant brands to see a recovery in customer traffic, leading to more rational competition [3] - Haidilao (06862) rose by 7%, while Jiumaojiu (09922) increased by over 5% [3] Group 4 - Qiutai Technology (01478) saw a 13% increase after issuing a profit warning, expecting a 400% to 450% year-on-year growth in comprehensive profit for the fiscal year 2025 [4]

活动现场，梅尔森医药总经理赵锡龙介绍了贝美净的研发历程与临床价值，北京天恒置业集团有限公司相关负责 人代表中国药登向梅尔森医药贝美净颁发中国药登首张海外版药品价格证明，为贝美净确立国际定价基准。 西城区相关负责人表示，首张海外版药品价格证明填补了我国商业药品价格认证在国际场景应用的空白，完善了 医药产业国际化服务支撑体系，向全球传递中国药品定价的专业性与规范性，为后续药企"出海"提供了可参考的 权威路径，将推动医药产业从"产品输出"升级为"标准赋能"，为中国药品走向全球市场、参与国际竞争，奠定了 坚实的合规与价值基础。 首张海外版药品价格证明在京发出（央广网记者 朱冠安 摄） 央广网北京1月13日消息（记者 朱冠安）1月13日，首张海外版药品价格证明颁发仪式暨贝美净全球首发价格发布 会在北京西城区举办。此举标志着中国药品价格登记系统（简称"中国药登"）在构建全球化、多元化的药品价格 体系方面取得实质性突破，为中国药品走向国际市场提供了权威价值认证。 记者了解到，中国药登独立于各省级医药采购平台，由西城区国资企业北京药品登记信息服务有限公司以社会化 模式运营，遵循"一地受理、全国共享、全球公开"原则，为国内外企 ...